XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Out-Licensing Agreements (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Feb. 21, 2022
USD ($)
item
agreement
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Collaborative agreements          
Product revenue, net   $ 26,972 $ 7,704 $ 59,161 $ 7,704
Collaboration revenue          
Collaborative agreements          
Product revenue, net       10,000  
Collaboration Agreements | Huadong rilonacept          
Collaborative agreements          
Notice period to terminate the agreement 12 months        
Collaboration Agreements | Huadong rilonacept          
Collaborative agreements          
Number of agreements entered into | agreement 2        
Upfront payments received $ 22,000        
Term of agreement for royalty payments 12 years        
Notice period to terminate the agreement if there is no material development or commercialization activities with respect to the licensed product in China 60 days        
Collaboration Agreements | Huadong rilonacept | Minimum          
Collaborative agreements          
Time period threshold of continuous material development or commercialization activities in China that, if not met, can trigger the right for the Company to terminate the agreement 6 months        
Territory License - Rilonacept | Huadong rilonacept          
Collaborative agreements          
Upfront payments received $ 12,000        
Number of performance obligations in an agreement | item 1        
Transaction price       12,000  
Territory License - Rilonacept | Huadong rilonacept | Maximum          
Collaborative agreements          
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones $ 70        
Territory License - Mavrilimumab | Collaboration revenue          
Collaborative agreements          
Product revenue, net       10,000  
Territory License - Mavrilimumab | Huadong rilonacept          
Collaborative agreements          
Upfront payments received $ 10,000        
Number of performance obligations in an agreement | item 2        
Transaction price       $ 10,000  
Territory License - Mavrilimumab | Huadong rilonacept | Maximum          
Collaborative agreements          
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones $ 576